Abstract
Human mesenchymal stem cells (hMSCs) are being considered for clinical trials of multiple sclerosis (MS). We examined the effects of adult bone marrow-derived hMSCs on responses of primary human Th1, Th17, and Th1/17 double-expressing T-cell subsets, all implicated in MS. As expected, soluble products from hMSCs inhibited Th1 responses; however, Th17 responses were increased. Secretion of interleukin (IL)-10, considered anti-inflammatory, was decreased. Pretreating hMSCs with the proinflammatory cytokine IL-1β accentuated these effects, and caused decreases in the Th1/17 subset. These findings underscore the importance of further preclinical work and immune-monitoring to define hMSC effects on disease-relevant immune responses under variable conditions.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antigens, CD / metabolism
-
CD4-Positive T-Lymphocytes / classification
-
CD4-Positive T-Lymphocytes / drug effects
-
CD4-Positive T-Lymphocytes / immunology*
-
Cell Proliferation / drug effects
-
Cells, Cultured
-
Culture Media, Conditioned / pharmacology
-
Cytokines / immunology
-
Cytokines / pharmacology
-
Enzyme-Linked Immunosorbent Assay / methods
-
Flow Cytometry / methods
-
Humans
-
Leukocytes, Mononuclear / drug effects
-
Leukocytes, Mononuclear / immunology
-
Lymphocyte Activation / immunology
-
Mesenchymal Stem Cells / chemistry
-
Mesenchymal Stem Cells / immunology*
-
T-Lymphocytes, Helper-Inducer / classification
-
T-Lymphocytes, Helper-Inducer / drug effects
-
T-Lymphocytes, Helper-Inducer / immunology
-
Th1 Cells / cytology*
-
Th1 Cells / immunology
Substances
-
Antigens, CD
-
Culture Media, Conditioned
-
Cytokines